DNA Nanobots Secures $3.5 Million Investment to Accelerate Non-Viral Gene Therapy Platform

COLUMBUS, Ohio--(BUSINESS WIRE)--DNA Nanobots, a pioneer in self-assembling nanoscale therapeutics, today announced it has secured $3.5 million in funding from a prominent, family office. This significant investment solidifies the company's operational runway for the next 18 months, enabling key advancements in its platform technology.

"We are very pleased to have successfully completed $3.5 million of our $5 million Seed round. This financing provides the capital needed to advance our programs and execute key value-creating milestones in 2026," said Jim Lynch, CEO of DNA Nanobots. "We are grateful for the strong support from our investors who have re-invested and share our vision and confidence in our strategy and team."

“We’re excited to see Ohio Life Sciences member DNA Nanobots secure $3.5 million in funding, a strong signal of confidence in Ohio’s life sciences ecosystem,” said Eddie Pauline, President and CEO of Ohio Life Sciences Association. “It’s encouraging to see capital flowing into Ohio-based companies, including innovative Ohio State spinouts that showcase the strength of our research, commercialization, and homegrown innovation.”

The funding will primarily be used to:

• Advance Pre-clinical Studies: Further optimize and test the efficacy of the self-assembling nanobot designs.
• Expand Production Capabilities: Strengthen in-house manufacturing infrastructure, enabling larger batch runs, and improved reproducibility.
• Expand IP Portfolio: Strengthen and broaden the intellectual property surrounding the company's core technology.
• Strategic Hires: Recruit specialized talent in molecular biology, nanotechnology, and engineering.

The Path to a Full Seed Round

With the anchor investment secured, DNA Nanobots is actively seeking to complete its Seed funding round. The company is currently targeting an additional $1.5 million investment to reach a final goal of $5 million for the Seed round. The completion of the Seed round will enable the company to initiate IND-enabling studies and fully prepare for its first-in-human clinical trials. Interested investors should reach out to Jim Lynch ([e-mail]).

About DNA Nanobots

DNA Nanobots is a privately held biotechnology company focused on developing the next generation of targeted nanomedicines. Utilizing precise DNA self-assembly (DNA origami), the company engineers nanobots designed to carry and release therapeutic payloads directly to diseased cells with unprecedented specificity, minimizing systemic toxicity, and maximizing treatment efficacy. DNA Nanobots deliver genes that are considered undeliverable. DNA Nanobots; reshaping gene therapy.